You are here

Category
Technology Name
Briefcase
Scientist
1751
Many cancer cells hijack and remodel existing metabolic pathways for their benefit. Specific targeting of these metabolic dependencies offers cancer patients increased efficiency and minimized side effects. Yet, the complexity of these pathways hinders the identification of targets. The present...

Many cancer cells hijack and remodel existing metabolic pathways for their benefit. Specific targeting of these metabolic dependencies offers cancer patients increased efficiency and minimized side effects. Yet, the complexity of these pathways hinders the identification of targets.
The present discovery elucidates the pathway by which argininosuccinate synthase (ASS1) down-regulation confer cancer progression. It shows that decreased activity of ASS1 in cancers supports proliferation by linking excess aspartate to pyrimidines synthesis. Importantly, these studies highlight Citrin (a mitochondrial aspartate transporter) inhibition as a potential method to decrease aspartate levels and selectively target this metabolic pathway in ASS1 depleted cancers.

Applications


  • Targeted Treatment for ASS1 depleted cancers.

Advantages


  • Targeted therapy, against a well defined pathway, increases the prospects for success.
  • Selective – targeting cancer metabolic dependency minimizes the chances for healthy cells damage that lead to side effects.

Technology's Essence


Cancer cells hijack and remodel existing metabolic pathways for their benefit in what is termed the Warburg effect. Researchers from Dr. Ayelet Erez's lab, at the Weizmann institute of Science, have delineated the metabolic benefit(s) conferred by loss of ASS1 to cancers. In agreement with previous experience, they found that ASS1 deficiency has an additional arginine- independent effect that is directly related to its substrate, aspartate.
By focusing on the relevant physiological and pathological model systems, it was found that ASS1 deficiency-mediated increase in aspartate levels lead to excessive proliferation through pyrimidine synthesis. The link between the two is provided by CAD (carbamoyl-phosphate synthase 2, aspartate transcarbamylase, dihydroorotase complex) and the mTOR signaling pathway.
Importantly, the present inventors have found that blocking Citrin, the mitochondrial aspartate transporter, rescues cell proliferation by reducing aspartate levels. Citrin may thus serve as a strong candidate for targeted therapy of ASS1 depleted cancers.   
Supporting this model, retrospective survival analysis of several cancers reveal that cancers with both decreased ASS1 expression and high Citrin levels have a trend for significantly worse prognosis.

+
  • Dr. Ayelet Erez
1670
A method for selective extraction of precious and rare metals has been developed at the Weizmann Institute. This method allows the efficient and environmentally benign recovery of precious materials that are currently discarded of in large quantities from spent catalysts (automotive and industrial)...

A method for selective extraction of precious and rare metals has been developed at the Weizmann Institute. This method allows the efficient and environmentally benign recovery of precious materials that are currently discarded of in large quantities from spent catalysts (automotive and industrial) from industrial processes (particularly in the electronic industry).

Prof. Igor Lubomirsky’s novel process is based on volatilization for selective extraction of precious and rare metals using benign metal salts, rather than dangerous chlorine gas as a chlorinating agent. The new process requires relatively low temperatures and is free from hazardous waste, among its additional advantages over conventional methods.

We believe that this efficient technology is key to increased reclaimed precious metals output, potentially resulting in the reduction of the demand for primary rare metals.

Applications


·           Recycling precious metals from spent items, e.g. platinum group metals from catalytic convertors


Advantages


·         No toxic input – chlorides are used rather than chlorine gas.

·         No hazardous waste is generated in the process.

·         Mild conditions. High-temperature furnaces and equipment are not required.

·         Relatively simple setup in comparison to conventional ones.

·         Small scale plants are economically viable.


Technology's Essence


Prof. Igor Lubomirsky and his group developed a novel method for the recovery of PGM from spent catalysts that can be applicable for other spent systems as well.

The method comprises of crushing the spent catalyst to obtain a catalyst particulate material with g a predetermined grain size and reacting it with chlorine containing salts rather than pure chlorine gas in a furnace at relatively low temperatures (900oC, far below the temperature required in the conventional volatilization method). This is followed by cooling the volatile PMG chloride product converting it into solid phase metal.

 

+
  • Prof. Igor Lubomirsky
  • Prof. Igor Lubomirsky
1716
An efficient and selective decomposition of plant biomass carbohydrates to their basic components, carbon monoxide and hydrogen, for use as syngas.Terrestrial plants contain about 70% hemicellulose and cellulose, which constitute a significant renewable bio-resource with potential as an alternative to...

An efficient and selective decomposition of plant biomass carbohydrates to their basic components, carbon monoxide and hydrogen, for use as syngas.
Terrestrial plants contain about 70% hemicellulose and cellulose, which constitute a significant renewable bio-resource with potential as an alternative to petroleum feedstock for carbon-based fuels. Traditional conversion of biomass to liquid fuels has been in the form of ethanol and bio-diesel, but this process is inefficient and much of the starting material is unusable and ultimately becomes waste.[1] Additionally, use of ethanol or bio-diesel is not universal to all engines as vehicles require specialized components to run on these fuels.
The presented technology allows for significantly greater efficiency in use of starting material, and the versatile final product of syngas, which can be a fuel itself or used as a fuel precursor in the well-known Fischer-Tropsch process to create hydrocarbons.[2] Alternatively, in a hydrogen economy scenario, this method can also be used to convert carbon monoxide to hydrogen via the water-gas shift reaction. Advantageously, both processes allow for the polyoxometalate (POM) catalyst to be reused without the need for recovery, which enables continuous use in a refinery setting.

Applications


  • Liquid hydrocarbon fuel synthesis from syngas
  • Entry into a new market – hydrogen production from biomass

Advantages


  • Efficient and complete breakdown of starting biomass material
  • Possible to produce hydrogen or syngas as product

Technology's Essence


The technology allows for preparation of syngas by reaction of a carbohydrate with a POM catalyst in the presence of a concentrated acid under anaerobic conditions, to yield carbon monoxide, followed by electrochemical release of hydrogen. This two-step process allows for easy separation and storage of the desired products. An alternative application of the same POM catalyst relates to a method for preparing formic acid in a similar method, but in a solvent consisting of a mixture of alcohol and water.
This reaction is based on the unexpected finding that POM catalysts, such as H5PV2Mo10O40, catalyze plant biomass derived polysaccharides of general form (CnH2nOn)m, with high selectivity and efficiency under mild conditions. Formation of CO occurs through an intermediate formation of formic acid and formaldehyde, and transformation of these transition compounds in concentrated acid results in the desired CO product. During this process, hydrogen atoms are stored on the POM catalysts as protons and electrons. Hydrogen gas is subsequently electrochemically released from the POM catalyst, which returns the catalyst to its original oxidized state and allows for continued reuse.

+
  • Prof. Ronny Neumann
1753
The Chiral Induced Spin Selectivity (CISS) effect, discovered in recent years by Prof. Ron Naaman from the Weizmann Institute of Science, implies that electrons transferred through chiral molecules possess a specific spin orientation. Hence, the molecular chirality and electron spin are correlated.A...

The Chiral Induced Spin Selectivity (CISS) effect, discovered in recent years by Prof. Ron Naaman from the Weizmann Institute of Science, implies that electrons transferred through chiral molecules possess a specific spin orientation. Hence, the molecular chirality and electron spin are correlated.
A team of researchers lead by Prof. Naaman have been investigating the CISS effect in different systems. They found that the high efficiency of many natural multiple electron reactions can also be attributed to spin alignment of the electrons involved.
The present innovation looks at hydrogen production through water electrolysis, showing that when using anodes coated by chiral molecules the efficiency of the electrolysis process increases by 30% compared to using uncoated, regular electrodes.

Applications


  • Control of electron spin
  • Significant reduction of over-potential in spin sensitive electrochemical reactions
  • Efficient electrochemical processes
  • Minimum side reactions

  • Advantages


     

    Technology's Essence


    Spin selective electrodes made from standard electrode material are coated with chiral molecules. These coated electrodes were used for electrolysis of water and showed superior efficacy compared to standard un-coated electrodes, by reduction of the over-potential required for the process. This is explained by the spin selective electron conduction through the chiral layer:

     

     

     

    Hydrogen production as a function of time for (A) the chiral molecules and (B) for the achiral molecules. The potentials in the brackets refer to the over-potential compared to DNA coated electrode. The measurements were conducted at the Eapp for each of the molecules.

     

    +
    • Prof. Ron Naaman
    1672
    Newly developed p53-reactivating peptides were shown to cause regression of very aggressive tumors in several cancer models. p53 is the most important  tumor suppressor gene. Mutant p53 forms can instigate a cascade of events that may lead to loss of control of cell growth and proliferation, and...

    Newly developed p53-reactivating peptides were shown to cause regression of very aggressive tumors in several cancer models. p53 is the most important  tumor suppressor gene. Mutant p53 forms can instigate a cascade of events that may lead to loss of control of cell growth and proliferation, and eventually to cancer. p53 is mutated in well over 50% of all tumors, making it the most frequently known mutated gene in human cancer. Most conventional chemotherapeutic and radio-therapeutic treatments activate p53 pathway and therefore have little effect on tumors harboring mutant-p53 forms. The p53 reactivating peptides are capable of changing the conformation of many forms of mutated p53 from mutant to wild-type form and restoring its tumor suppression functions. Hence, they have the potential to benefit up to 50% of cancer patients – patients who currently have very poor response to the conventional cancer treatments.

    Applications


    ·         A potential first line therapy for mutant p53-bearing cancers

    ·         A potential combination treatment with Chemotherapy and other means of cancer therapy


    Advantages


    ·         Suitable for treatment of about 50% of cancer patients, in which conventional treatments show poor results.

    ·         Based on restoring the natural tumor-suppression mechanisms


    Technology's Essence


    The proposed technology is based on the development of peptides that are capable of changing the conformation of p53 from mutant to wild-type form and restoring its tumor suppression functions. The peptides were generated using Phage Display technique and screened so that only peptides capable of shifting the equilibrium towards the wild type conformation of p53 were selected. Preliminary pre-clinical experiments show that these p53-reactivating peptides cause regression of very aggressive tumors in several cancer models. Hence, the p53 reactivating peptides have the potential to benefit up to 50% of cancer patients – patients who currently have very poor response to the conventional cancer treatments.

    +
    • Prof. Varda Rotter
    • Prof. Moshe Oren
    1722
    Our technology provides a new type of oxidative cleavage reaction of organic compounds with highly selective product formation.Polyoxometalate (POM) catalysts have become well-known for their utility and diversity in specific reactions. Through the elucidation of POM catalytic pathways, greater...

    Our technology provides a new type of oxidative cleavage reaction of organic compounds with highly selective product formation.
    Polyoxometalate (POM) catalysts have become well-known for their utility and diversity in specific reactions. Through the elucidation of POM catalytic pathways, greater versatility has been achieved. This technology is one such application of a novel POM catalyst and is exploited to cleave carbon-carbon double bonds in alkenes (olefins) through an aerobic oxidation reaction. Oxidation reactions are of particular interest because they are difficult to achieve on an industrial scale while maintaining “green” chemistry practices. [1]

    --------------------------------------------------------------------------------
    [1] Green Chem., 2007, 9, 717-730

    Applications


    • As a novel catalyst in industrial organic chemistry processes
    • Sold as a stand-alone catalyst for laboratory or individual use

    Advantages


    • Environmentally friendly oxidation reaction
    • Easy catalyst regeneration

    Technology's Essence


    Our approach is motivated by societal considerations that demand environmentally benign and sustainable solutions for oxidative reactions. As such, we have developed a scheme to react NO2 with a transition-metal-substituted POM which yields a metal-nitro intermediate that is competent for forming the precursors for oxidation with molecular oxygen, O2, to have a final product of ketones and/or aldehydes, and regenerate the POM catalysts.[1]
    This method has preference towards di/tri-substituted alkenes. High yields of ketones or aldehydes have been produced and the POM catalyst is regenerated without further oxidation to carboxylic acids, as is typical with other oxidative catalysts.
    The selective cleavage of carbon-carbon double or triple bonds with metal-nitro or metal-nitrito compound has not been reported. This exciting new discovery could lead to a wide variety of organic reactions not previously possible, along with revolutionary green oxidative chemistry techniques.

    --------------------------------------------------------------------------------
    [1] J. Am. Chem. Soc., 2014, 136(31), pp10941-10948 

    +
    • Prof. Ronny Neumann
    1679
    A novel therapy for Triple Negative Breast Cancer (TNBC) using mAbs combinationBreast cancer is the most common cancer in women worldwide. Triple-negative breast cancer (TNBC) representing about 15% of all breast cancer cases, is the deadliest form of all breast cancer subtypes, and tends to affect...

    A novel therapy for Triple Negative Breast Cancer (TNBC) using mAbs combination
    Breast cancer is the most common cancer in women worldwide. Triple-negative breast cancer (TNBC) representing about 15% of all breast cancer cases, is the deadliest form of all breast cancer subtypes, and tends to affect women at a younger age. Unfortunately TNBC cannot be treated with the common receptor targeted therapies since it does not express these targets, the estrogen, progesterone and Her2/neu receptors. Therefor systemic treatment options are currently limited to cytotoxic chemotherapy. The lack of effective targeted therapies, resistance to chemotherapy, and early metastatic spread have contributed to the poor prognoses and outcomes associated with TNBC.
    The current technology offers a novel therapeutic strategy for TNBC. The application of two novel, noncompetitive antibodies against EGFR, achieves a robust degradation EGFR resulting in tumor inhibition.

    Applications


    • Novel and unique antibody targeted therapy for TNBC.
    • The novel anti EGFR antibodies can cooperate synergistically with the currently marketed EGFR antibodies.

    Advantages


    • A promising therapeutic scenario to treat TNBC.
    • Enhanced EGFR degradation and improved anti-tumor activity, in contrast to clinically approved anti-EGFR mAbs, which display no cooperative effects.
    • Lysosomal EGFR degradation pathway induced by epitope-distinct antibody mixture may potentially lead to improved therapeutic outcome, and reduced resistance.

    Technology's Essence


    Prof. Yosef Yarden and his team demonstrated that a combination of novel antibodies that target distinct regions on the human EGF receptor resulted in its robust and synergistic down-regulation, leading to pronounced tumor growth inhibition. Furthermore, the combined mAbs induced lysosomal degradation of EGFR, while avoiding the recycling route. Such irreversible mode of EGFR degradation may potentially increase response rate or delay the onset of patient resistance.
    Conversely, combining cetuximab and panitumumab, the mAbs routinely used to treat colorectal cancer patients, did not improve receptor degradation because they are both attracted to the same epitope on EGFR.

    +
    • Prof. Yosef Yarden
    1772
    MTCH2 as a novel target for the treatment of obesity.Obesity is an escalating public health problem with an increasing prevalence worldwide, and a primary contingency of many life-threatening diseases, as well as early mortality. In the U.S. alone, more than one-third of adults are obese. Obesity-...

    MTCH2 as a novel target for the treatment of obesity.
    Obesity is an escalating public health problem with an increasing prevalence worldwide, and a primary contingency of many life-threatening diseases, as well as early mortality. In the U.S. alone, more than one-third of adults are obese. Obesity-related conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some of the leading causes of preventable death. Physicians and patients alike consider the weight-loss efficacy of the current therapeutics to be unsatisfactory. Therefore, there is an unmet need for innovative options that are at once safe and efficacious, and allow the patient to maintain weight loss.
    The present invention describes the identification of Mitochondrial Carrier Homolog 2 (MTCH2) as a novel player in muscle metabolism and the therapeutic potential of inhibiting MTCH2 for the treatment of diet-induced obesity and diabetes.

    Advantages


    • A fresh approach for targeting weight-related disorders
    • Direct effect on metabolism instead of indirect mechanisms of current therapeutics which target appetite modulation.
    • Protection from diet-induced obesity can be used as a prevention treatment for people with a tendency for weight gain.  

    Technology's Essence


    MTCH2 functions as a receptor-like protein for the pro-apoptotic BID protein in the mitochondria.
    MTCH2 was identified as one of six new gene loci associated with Body Mass Index (BMI) and obesity in humans suggesting that MTCH2 may also play a role in metabolism.
    MTCH2 was recently shown by the Gross’s lab to also function as a repressor of   mitochondria oxidative phosphorylation (OXPHOS) in the hematopoietic system.
    Deletion of MTCH2 in skeletal muscle increases mitochondrial OXPHOS and mass, and increases capacity for endurance exercise. In addition, loss of MTCH2 increases mitochondria and glycolytic flux in muscles as measured by monitoring pyruvate and lactate levels.
    MTCH2 knockout mice are protected from diet-induced obesity, hyperinsulinemia, and are more prone to weight loss upon caloric restriction.
    Therefore, the association of MTCH2 with mitochondrial function offers a potential novel target for muscle metabolism modulation in the fight against metabolic disorders such as obesity and diabetes.

     

    +
    1733
    The spatial distribution of proteins inside the cell is under tight regulation. This regulation is necessary to ensure proper functioning of the cell, and is of particular importance when extracellular stimulation is applied. Upon stimulation, many signaling proteins rapidly and dynamically change...

    The spatial distribution of proteins inside the cell is under tight regulation. This regulation is necessary to ensure proper functioning of the cell, and is of particular importance when extracellular stimulation is applied. Upon stimulation, many signaling proteins rapidly and dynamically change their location. Today, there is a widely recognized need to identify novel sequences which regulates nuclear translocation.
    Recently, Prof. Zeger and his team discovered a new level of regulation to stimulated transcription. They showed that ?-like importunes are central mediators of nuclear translocation of signaling proteins. Furthermore they identified the site of interaction and designed accordingly a peptide which was found to prevent nuclear translocation.
    This technology presents peptides with the potential of treating inflammatory and immune disease by regulating (prevent or promote) the translocation of proteins into the nucleus.

    Applications


    • Inflammation
    • Immune diseases

    Advantages


    • Effective
    • Safe

    Technology's Essence


    The researchers found that ?-like importins play a key role in JNK and p38 translocation. They also found that the translocation of these MAPKs is mediated by the formation of either Imp3/Imp7/MAPK or Imp3/Imp9MAPK heterodimers. Most importantly, the researchers identified the site in p38 that mediate the interaction with Imp7 and Imp9 and showed that the important sequence lies within residues 20-30 of p38?. Subsequently they synthesized a 14 amino acid myristoylated peptide based on the sequence of residues 21-34 of p38?. When it was applied to HeLa cells prior to stimulation, it prevented the nuclear translocation and Imp7/9 interaction of the MAPKs. Since the peptides of this technology are able to specifically inhibit the nuclear activities of p38 (such as inflammatory activities) without modulating their cytoplasmic activities, these peptides may serve as a therapeutic agent for inflammatory and apoptosis related diseases without having side effect.

     

    +
    • Prof. Rony Seger
    1704
    Neuropathic Gaucher’s (nGD), is a rare but very severe manifestation of the disease, with a varying degree of involvement of the central nervous system, in addition to systemic symptoms. As of today, there is no cure for these severe conditions. The search for such cure is tremendously hindered by the...

    Neuropathic Gaucher’s (nGD), is a rare but very severe manifestation of the disease, with a varying degree of involvement of the central nervous system, in addition to systemic symptoms. As of today, there is no cure for these severe conditions.
    The search for such cure is tremendously hindered by the unmet need for a reliable biochemical biomarker for nGD.
    The present invention identifies the glycoprotein non-metastatic B (GPNMB) as a potential powerful nGD biomarker for use in early diagnosis, determination of disease severity, as well as a straight forward readout in clinical and preclinical experiments.

    Applications


    Diagnosis and drug development for neuropathic GD

    Advantages


    Straight forward diagnostic tool – based on standard biochemical assays
    Relatively simple clinical procedure – samples are collected from CSF and not brain
    High sensitivity – for the diagnosis of disease severity
    Compatible with preclinical experiments

    Technology's Essence


    Prof. Futerman and his team preformed a quantitative global proteomic analysis (using LC-MS/MS) of cerebrospinal fluid (CSF) samples from four patients with Type 3 GD, to identify mis-regulated proteins, compared with healthy subject.
    Glycoprotein non-metastatic B (GPNMB), a protein that was previously associated with several lysosomal storage disorders, exhibited very high levels (a 42-fold increase) in the CSF of type 3 GD patients.  Two peptides were identified from GPNMB, both located in the non-cytosolic domain, suggesting that GPNMB is cleaved and secreted into the CSF from the brain. LC-MS/MS results were validated by ELISA and by western blot analysis in CSF and in human brain samples.
    Several proof of principle experiments were conducted in order to prove the validity of using GPNMB as a biomarker for monitoring disease state and treatments efficacy in neuropathic GD in patients and mouse models:
    GPNMB levels were shown to be correlated with the severity of type 3 Gaucher’s disease patients, as measured by lower IQ score and lower score in Purdue Pegboard test, assessing eye-hand coordination. In addition, using conduritol b epoxide (CBE)-injection based mouse model that simulate different severities and recovery periods, it was shown that GPNMB levels rapidly rise or decline to reliably reflect progress/remission states of the diseases.

    +
    • Prof. Anthony H. Futerman
    1800
    A new software tool used for the removal of artifacts from transcranial magnetic stimulation (TMS) triggered electroencephalography (EEG) was developed by the group of Prof. Moses. The combined use of TMS with EEG allows for a unique measurement of the brain's global response to localized and abrupt...

    A new software tool used for the removal of artifacts from transcranial magnetic stimulation (TMS) triggered electroencephalography (EEG) was developed by the group of Prof. Moses.

    The combined use of TMS with EEG allows for a unique measurement of the brain's global response to localized and abrupt stimulations. This may allow TMS-EEG to be used as a diagnostic tool for various neurologic and psychiatric conditions.

    However, large electric artifacts are induced in the EEG by the TMS, which are unrelated to brain activity and obscure crucial stages of the brain's response. These artifacts are orders of magnitude larger than the physiological brain activity, and persist from a few to hundreds of milliseconds. However, no generally accepted algorithm is available that can remove the artifacts without unintentionally and significally altering physiological information.

    The software designed according to the model along with a friendly GUI is a powerful tool for the TMS-EEG field. The software has tested and proven to be effective on real datasets measured on psychiatric patients.

    Applications


    • TMS triggered EEG diagnostics

    Advantages


    • Easy to use software with a GUI
    • Exposes the full EEG from the brain

    Technology's Essence


    The new software tool is based on the observation that, contrary to expectation, the decay of the electrode voltage after the TMS pulse is a power law in time rather than an exponential. A model based on two dimensional diffusion of the accumulated charge from the high electric
    fields of the TMS in the skin was built. This model reproduces the artifact precisely, including the many perplexing artifact shapes that are seen on the different electrodes. Artifact removal software based on this model exposes the full EEG from the brain, as validated by continuously reconstructing 50Hz signals that are the same magnitude as the brain signals.

    +
    • Prof. Elisha Moses
    1750
    Organophosphates are toxic compounds found in chemical warfare agents, such as nerve gases, and insect pesticides.Use of volatile nerve gas agents by terrorist organizations is a key concern of governments around the world. V-type nerve agents (e.g. VX, RVX, and CVX) are particularly toxic nerve gases...

    Organophosphates are toxic compounds found in chemical warfare agents, such as nerve gases, and insect pesticides.
    Use of volatile nerve gas agents by terrorist organizations is a key concern of governments around the world. V-type nerve agents (e.g. VX, RVX, and CVX) are particularly toxic nerve gases, with an exceptionally high potency. Although not as lethal as nerve agents, organophosphate insecticides can be harmful in large or prolonged doses. The standard therapy has limited efficacy, carry risks of serious adverse effects and have relatively short shelf life in field conditions.
    Bioscavengers represent a preferred to rapidly detoxify organophosphates in the blood, before they had the chance to reach its physiological targets and cause damage, but usually require the use of very high doses.
    The present invention provides genetically modified phosphotriesterase (PTE) variants, which serve as catalytic bioscavengers for V-type nerve agents, with exceptional detoxification activity at low doses, and improved stability.

    Applications


    • Prophylactic or post exposure treatment for nerve gases attack, in particular V-type agents
    • Treatment for pesticides poisoning

    Advantages


    • High catalytic activity – allow high efficacy at low doses
    • Reduced effective doses allows to reduce adverse effects
    • High stability increasing shelf life
    • Compatible with both prophylaxis and post exposure
    • Compatible for both surface decontamination and administration to patients

    Technology's Essence


    Researchers at Prof. Tawfik lab use directed evolution to drive protein mutagenesis towards desired traits. Appling this approach, using the actual threat agents, the present inventors generated recombinant phosphotriesterase (PTE) variants with improved catalytic efficiencies towards V-type nerve agent hydrolysis. Serving as catalytic bioscavengers, these recombinant PTE variants hydrolyze organophosphates without being consumed and thus can be applied at low doses (catalytic efficiency (kcat/KM) greater than 3.106 M-1min-1).
    Importantly, PTE is efficient both as a prophylactic agent that may be given several hours prior to exposure as a preventive measure, and as post exposure antidote, even days after in a single or multiple-doses.
    It is compatible with both decontamination of surfaces and detoxification administrated to a patient by standard routes such as orally or injectables.
    Finally, some PTE variants show superior stability properties, retaining at least 50% of their catalytic activity at 50?C, indicating extended shelf life. This may be especially critical in field conditions, where the risk for nerve agent exposure is high.

    +
    • Prof. Dan S. Tawfik
    1665
    Improved magnetic resonance imaging (MRI) for cardiac fibrosis and other fibrotic diseases.Myocardial fibrosis is associated with worsening ventricular systolic function, abnormal cardiac remodeling, and increased ventricular stiffness, significantly increasing the risk of adverse cardiac outcomes....

    Improved magnetic resonance imaging (MRI) for cardiac fibrosis and other fibrotic diseases.
    Myocardial fibrosis is associated with worsening ventricular systolic function, abnormal cardiac remodeling, and increased ventricular stiffness, significantly increasing the risk of adverse cardiac outcomes. Hypertension and diabetes elicit fibrotic processes in the heart, placing a high percentage of the western world population at risk, yet the early identification of fibrotic development in high-risk patients is hindered by lack of adequate fibrosis imaging modalities. This in turn leads to increased morbidity and additional financial burden to health care services. The current standard method to assess myocardial fibrosis employs the usage of MRI coupled with intravenous infusion of Gadolinium contrast agent. However, this method suffers from considerable drawbacks including reduced sensitivity (that permits diagnosis only at advanced stages of disease), lengthy scan times and toxicity of the contrast agent, which excludes a significant subset of patient populations from diagnosis. Thus, the capacity to diagnose myocardial fibrosis in its early stages would allow successful therapeutic intervention, and may also create a platform for the non-invasive study of fibrotic development, thereby facilitating the design of targeted therapies. The current invention is comprised of a novel cardiovascular magnetic resonance method with enhanced sensitivity, without the need for contrast agent administration.

    Applications


    • Detection of cardiac fibrosis due to various pathologies, including hypertension, diabetes and heart failure.
    • The method can be applied to detect fibrotic tissues in a broad range of disorders including cancer, renal fibrosis and pathologies related to skeletal muscles.
    • A platform for the clinical study of targeted therapies that may prevent or arrest fibrotic diseases.
    • Monitoring the efficacy of treatment tailored to target fibrotic tissue development.

     


    Advantages


    • The method relies on magnetization transfer to provide contrast, and therefore obviates the need for any extrinsic, toxic contrast agent such as Gadolinium.
    • Improved sensitivity over current contrast agent-based cardiac MRI methods.
    • The method can be readily applied to existing MRI clinical imaging systems.

    Technology's Essence


    A team of researchers at the Weizmann Institute has developed a novel approach for detection of myocardial fibrosis using magnetization transfer contrast (MCT) MRI cardiac imaging technology. The method was tested in vivo on animal models of heart failure and proved highly sensitive for detection of scar tissue formation and monitoring of fibrotic development. One prominent advantage of the present technology over current cardiac imaging modalities is that it eliminates the requirement for extrinsic contrast agents, thereby circumventing potential adverse toxic side effects.

    +
    • Prof. Michal Neeman
    1712
    • Prof. Yechiel Shai
    1802
    A new signal processing tool for the detection of pulses travelling through media with complex or unknown dispersion properties was developed by the group of Prof. Gal-Yam, originally for detecting radio bursts in astronomical observations. Pulses are applied in various fields such as oil & gas...

    A new signal processing tool for the detection of pulses travelling through media with complex or unknown dispersion properties was developed by the group of Prof. Gal-Yam, originally for detecting radio bursts in astronomical observations.
    Pulses are applied in various fields such as oil & gas exploration, detection (e.g. sonar, lidar and radar) and communication. When pulses pass through dispersive media, the arrival times at the detector of different frequency components may differ, and as a result the pulse may become degraded (e.g. transformed to a longer pulse with reduced intensity), even to the level of becoming indistinguishable in terms of signal to noise. This problem becomes even more challenging when detecting short pulses that travel through complex or unknown media.
    The new method presented here provides a proven and efficient solution that can be applied for different scenarios where short pulses dispersed by complex media are used. 

    Applications


    • Detection and surveying technologies- sonar, lidar, radar etc

    Advantages


    • Efficient, requires limited computational resources
    • Generic, can be applied to various setups
    • Easily implementable into existing systems

    Technology's Essence


    The method includes obtaining an input array of cells, each indicating an intensity of a frequency component of the signal at a representative time. A fast dispersion measure transform (FDMT) is applied to concurrently sum the cells of the input array that lie along different dispersion curves, each curve defined by a known non-linear functional form and being uniquely characterized by a time coordinate and by a value of the dispersion measure. Application of FDMT includes initially generating a plurality of sub-arrays, each representing a frequency sub-band and iteratively combining pairs of adjacent sub-arrays in accordance with an addition rule until all of the initially generated plurality of sub-arrays are combined into an output array of the sums, in which a cell of the output array that is indicative of a transmitted pulse is identified.

    +
    • Prof. Avishay Gal-Yam

    Pages